摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(1H-benzimidazol-2-yl)pyridin-2-amine | 879884-04-5

中文名称
——
中文别名
——
英文名称
5-(1H-benzimidazol-2-yl)pyridin-2-amine
英文别名
——
5-(1H-benzimidazol-2-yl)pyridin-2-amine化学式
CAS
879884-04-5
化学式
C12H10N4
mdl
MFCD08271854
分子量
210.23
InChiKey
VIHRGSUFMGKDHL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    492.4±55.0 °C(Predicted)
  • 密度:
    1.348±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.6
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2019049061A1
    公开(公告)日:2019-03-14
    The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言,本发明涉及根据公式(lb)的化合物,其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义;或其盐,包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白(c-MYC)和/或抑制p300/CBP组蛋白乙酰转移酶,可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、屑病、屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症,以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此,本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物,降低细胞中MYC蛋白(c-MYC)和抑制p300/CBP组蛋白乙酰转移酶活性的方法,以及治疗与之相关的疾病的方法。
  • BIOFILM-REMOVING AGENT
    申请人:Isobe Kazuo
    公开号:US20100261631A1
    公开(公告)日:2010-10-14
    A biofilm-removing agent which effectively removes biofilms is provided. A biofilm-removing agent containing a basic amino acid derivative represented by the following formula (1) or a salt thereof: (wherein R 1 represents a linear- or branched-alkyl group having 4 to 18 carbon atoms or a linear- or branched-alkenyl group having 4 to 18 carbon atoms; X and Y each represent a group selected from the groups represented by the following formulas: and m represents an integer from 1 to 5).
    提供了一种有效去除生物膜的生物膜去除剂。该生物膜去除剂含有由以下式(1)表示的碱性氨基酸生物或其盐:(其中R1表示具有4至18个碳原子的线性或支链烷基或具有4至18个碳原子的线性或支链烯基;X和Y各代表从以下式表示的群中选择的群;m代表1至5的整数)。
  • Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
    申请人:Xenon Pharmaceuticals Inc.
    公开号:EP1807085B1
    公开(公告)日:2013-08-21
  • THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20090054410A1
    公开(公告)日:2009-02-26
    This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.
  • US8382912B2
    申请人:——
    公开号:US8382912B2
    公开(公告)日:2013-02-26
查看更多